Rejected Valeant aims to replace Cephalon board

Cephalon isn't going to be an easy mark for would-be buyer Valeant Pharmaceuticals. Despite perceived weakness in the wake of its founder's death, Cephalon is rejecting Valeant's $73-per-share bid as "opportunistic" and much too cheap. So, Valeant chief J. Michael Pearson has a fight on his hands.

If Pearson wants to follow through, then he may have to set aside his desire to wrap up a deal quickly, analysts said. Cowen & Co's Eric Schmidt figures that Valeant will have to raise its price to $75 to $80 per share--and that the back-and-forth "will take a couple months," Bloomberg reports. "There will be a dance and courtship and there will be a deal at the end of that process," Schmidt said.

But Pearson has already made his next move. Valeant has proposed a slate of seven new directors to replace Cephalon's board and push through a deal. "We continue to strongly believe that it is in the best interests of both Valeant's and Cephalon's stockholders to resolve this matter quickly, one way or the other," Pearson said in a statement. "Valeant will move fast. We had hoped that Cephalon would do the same. Now, it will be in the stockholders' hands."

- check out Cephalon's release
- find the statement from Valeant
- see the Bloomberg story
- get more from the Wall Street Journal
- read the Reuters article

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.